BIO-RAD LABORATORIES -CL B (BIO.B) Forecast, Price Target & Analyst Ratings
NYSE:BIO.B • US0905721082
281.95 USD
+13.06 (+4.86%)
Last: Mar 4, 2026, 08:10 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIO-RAD LABORATORIES -CL B (BIO.B).
Forecast Snapshot
Consensus Price Target
$342.51
+ 21.48% Upside
Next Earnings Forecast
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate$2.00
Revenue Estimate591.52M
ChartMill Buy Consensus
76.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$342.51
Upside
+ 21.48%
From current price of $281.95 to mean target of $342.51, Based on 10 analyst forecasts
Low
$283.47
Median
$342.51
High
$394.68
Price Target Revisions
1 Month
-5.79%
3 Months
-5.79%
Price Target Summary
10 analysts have analysed BIO.B and the average price target is 342.51 USD. This implies a price increase of 21.48% is expected in the next year compared to the current price of 281.95.
The average price target has been revised downward by 5.79% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
76.00%
BIO.B was analyzed by 10 analysts. The buy percentage consensus is at 76. So analysts seem to be have mildly positive about BIO.B.
In the previous month the buy percentage consensus was at a similar level.
BIO.B was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2021-07-30 | Wells Fargo | Maintains | Overweight |
| 2021-02-12 | Citigroup | Maintains | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateApr 29, 2026
PeriodQ1 / 2026
EPS Estimate$2.00
Revenue Estimate591.52M
Revenue Q2Q1.05%
EPS Q2Q-21.28%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
-2.46%
Revenue (3 Months)
-2.59%
EPS (1 Month)
-20.96%
EPS (3 Months)
-21.27%
Next Earnings Summary
BIO.B is expected to report earnings on 4/29/2026. The consensus EPS estimate for the next earnings is 2 USD and the consensus revenue estimate is 591.52M USD.
The next earnings revenue estimate has been revised downward by 2.59% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 2.671B -4.67% | 2.567B -3.92% | 2.583B 0.65% | 2.648B 2.51% | 2.732B 3.17% | 2.804B 2.64% | 2.853B 1.75% | 2.949B 3.36% | |
| EBITDA YoY % growth | N/A -19.14% | N/A -8.95% | N/A -3.93% | 457.38M 0.66% | 489.36M 6.99% | 501.54M 2.49% | 480.76M -4.14% | 496.92M 3.36% | |
| EBIT YoY % growth | 365.696M -24.88% | 298.5M -18.37% | 266.1M -10.85% | 317.53M 19.33% | 349.02M 9.92% | 362.1M 3.75% | N/A | N/A | |
| Operating Margin | 13.69% | 11.63% | 10.30% | 11.99% | 12.78% | 12.91% | N/A | N/A | |
| EPS YoY % growth | 11.77 -17.29% | 10.31 -12.40% | 9.92 -3.78% | 10.37 4.57% | 11.48 10.68% | 12.19 6.17% | 9.84 -19.30% | 10.21 3.80% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 2.00 -21.28% | 2.55 -2.27% | 2.59 14.57% | 2.92 16.22% | 3.06 52.80% | 3.01 18.19% | 2.94 13.70% | 3.24 11.14% |
| Revenue Q2Q % growth | 591.52M 1.05% | 664.85M 2.03% | 678.27M 3.87% | 723.64M 4.39% | 641.59M 8.46% | 704.48M 5.96% | 696.02M 2.62% | 759.27M 4.92% |
| EBITDA Q2Q % growth | 84.853M 1.07% | 119.21M 25.68% | 124.91M 22.16% | 135.71M 6.62% | 124.51M 46.74% | 142.93M 19.90% | 134.97M 8.05% | 147.06M 8.36% |
| EBIT Q2Q % growth | 48.875M -14.10% | 83.162M 4.61% | 86.737M 27.93% | 99.694M 61.06% | 85.921M 75.80% | 104.37M 25.50% | 96.824M 11.63% | 108.71M 9.04% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
7.11%
EPS Next 5 Year
0.58%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
2.54%
Revenue Next 5 Year
2.54%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
17.21%
EBIT Next 5 Year
9.79%
BIO-RAD LABORATORIES -CL B / BIO.B Forecast FAQ
What is the average price target for BIO-RAD LABORATORIES -CL B (BIO.B) stock?
10 analysts have analysed BIO.B and the average price target is 342.51 USD. This implies a price increase of 21.48% is expected in the next year compared to the current price of 281.95.
Can you provide the upcoming earnings date for BIO-RAD LABORATORIES -CL B?
BIO-RAD LABORATORIES -CL B (BIO.B) will report earnings on 2026-04-29, after the market close.
What are the consensus estimates for BIO-RAD LABORATORIES -CL B (BIO.B) next earnings?
The consensus EPS estimate for the next earnings of BIO-RAD LABORATORIES -CL B (BIO.B) is 2 USD and the consensus revenue estimate is 591.52M USD.
How do analysts rate BIO-RAD LABORATORIES -CL B (BIO.B)?
The consensus rating for BIO-RAD LABORATORIES -CL B (BIO.B) is 76 / 100 . This indicates that analysts generally have a positive outlook on the stock.